编号：2021-12-07 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-05-09 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|----------------------------------------------------------|-------|-------| | | | | | | | | | | | | | □特定对象调研 □分析师会议 | | | | | | | | | □媒体采访 | √ 业绩说明会 | ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-05-19 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------|-------------------------------------------------------------------------|--------------------------------------------------|--------------|-------|-------|-------|-------|---------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | | | | 特定对象调研 □分析师会议 | | | | ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-05-05 | --- | --- | --- | |--------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | 10:00-11:00 | 华安证券、亚洲红马投资集团、中华出版促进会、熙德博远资 | | | 15:00-16:00 | 本、德邻众福投资、红土创新、申万菱信 华鑫证券、华泰证券、万家基金、英 ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-05-13 | --- | --- | --- | |-------------------------|--------------------------------------|------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | √ 业绩说明会 | | 投资者关系活 | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 投资者网上提问 | | | | 1、2022 年 5 月 12 日 | (周四) 下午 15:00-16:30 | | 时间 | 2、2022 年 5 月 13 日 | (周五) 下午 15: ...

证券代码：002864 证券简称：盘龙药业 债券代码：127057 债券简称：盘龙转债 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-06-20 | --- | --- | --- | |-------------------------|----------------------------------|----------------------------------------------------------------------------| | | | 特定对象调研 □分析师会议 | | | □媒体采访 | □业绩说明会 | | 投资者关系活 | □新闻发布会 □路演活动 | | | 动类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 德邦证券、华创证券、龙航资产、诺安基金 | | 时间 | 2022 年 06 月 20 | 日（星期一） 15:00-16:00 | | 地点 | 电话会议 | | | 上市公司接待 | | 集团副总经理兼董秘吴杰；集团财务总监祝凤鸣；盘龙药业市场部总监韩腾 | | ...

编号：2022-11-10 证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------|---------------------------------------------------------------------| | | | | | | √特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活 | □新闻发布会 | 路演活动 | | 动类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 西部证券、中银基金 | | | 时间 | 2022 年 11 月 10 | 日（星期四） 15:00-16:00 | | 地点 | 线上会议 | | | 上市公司接待 | | 集团副总经理兼董秘吴杰先生、集团副总经理兼盘龙医药研究院院长张德柱 | | 人员姓名 | 先生、集团市场部总监韩腾飞先生 | | | | Q ...

证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2022-11-02-1 | --- | --- | --- | |-------------------------|----------------------------------|------------------------------------------------------------------------| | | √ 特定对象调研 | □分析师会议 | | 投资者关系活 | □媒体采访 □业绩说明会 | | | 动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 国泰基金、西部证券、上海尚近投资 | | | 时间 | 2022 年 11 月 02 | 日（星期三） 10:00-10:40 | | 地点 | 线上电话会议 | | | | | 集团副总经理兼董秘吴杰先生、集团总经理助理兼投资规划部总监赵庆波女 | | 上市公司接待 人员姓名 | | 士、集团市场部总监韩腾飞先生、 ...

证券代码：002864 证券简称：盘龙药业 编号：2022-11-02-2 | --- | --- | --- | |-------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | | | | | √ 特定对象调研 | □分析师会议 | | 投资者关系活 | □媒体采访 □业绩说明会 | | | 动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 国泰基金、华安证券 | | | 时间 | 2022 年 11 月 02 | 日（星期三） 13:30-15:00 | | 地点 | 线上电话会议 | | | 上市公司接待 人员姓名 | | 集团副总经理兼董秘吴杰先生、集团财务总监祝凤鸣先生、集 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥262,473,046.87, an increase of 18.69% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥33,099,197.05, reflecting a growth of 7.86% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.3900, up by 8.76% from the previous year[5] - Total operating revenue for Q3 2022 reached CNY 693,447,695, an increase of 11.4% compared to CNY 622,648,763.48 in the same period last year[25] - Net profit for Q3 2022 was CNY 79,940,900.98, representing a growth of 7.6% from CNY 74,619,007.52 in Q3 2021[26] - Earnings per share (EPS) increased to CNY 0.9100 from CNY 0.8542, marking a rise of 6.7%[27] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥1,807,260,234.39, representing a 35.87% increase from the end of the previous year[5] - Total assets as of the end of Q3 2022 were CNY 1,807,260,234.39, compared to CNY 1,330,174,616.17 at the end of the previous year, indicating a growth of 35.7%[24] - Total liabilities increased to CNY 884,373,441.39, up from CNY 522,967,375.29, reflecting a significant rise of 68.9%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥114,832,020.89, a rise of 39.92% compared to the same period last year[12] - Operating cash inflow for the period was $763,137,296.85, an increase of 12.83% from $676,397,253.14 in the previous period[29] - Net cash flow from operating activities was $114,832,020.89, up 39.9% compared to $82,068,441.30 in the prior period[30] - Cash inflow from financing activities reached $445,510,975.56, significantly higher than $52,522,765.54 in the previous period[31] - Net cash flow from financing activities was $317,770,977.55, compared to $13,132,383.12 in the prior period, indicating a substantial increase[31] Investments and Expenses - Research and development expenses for Q3 2022 were ¥9,157,723.10, marking a 54.86% increase year-on-year[11] - The company reported a research and development expense of CNY 9,157,723.10, which is an increase of 55.5% from CNY 5,913,641.02 in the previous year[25] - The company’s long-term equity investments reached ¥9,882,181.84, attributed to investments in the Qinlong Yaokang Fund[11] - Cash outflow for investment activities was $63,099,088.08, compared to $62,065,480.22 in the previous period, indicating a slight increase[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,817[14] - The largest shareholder, Xie Xiaolin, holds 42.88% of the shares, amounting to 37,171,000 shares[14] Stock and Incentive Plans - The company plans to grant 1,126,400 restricted shares at a price of ¥13.38 per share as part of its 2022 incentive plan[17] - The company has not completed the share registration procedures for the restricted stock incentive plan as of the report date[17] - The company issued 2,760,000 convertible bonds with a total amount of ¥276,000,000, netting approximately ¥271,984,367.92 after expenses[17] - As of September 30, 2022, 3,511 convertible bonds have been converted into 13,237 shares, representing 0.02% of the total shares outstanding[18] Current Assets - As of September 30, 2022, the company's cash and cash equivalents reached ¥788,808,577.26, an increase from ¥419,304,666.90 at the beginning of the year[21] - The total current assets as of September 30, 2022, amounted to ¥1,381,559,794.16, up from ¥956,446,085.23 at the beginning of the year[21] - Accounts receivable increased to ¥408,749,392.10 from ¥361,350,459.45, reflecting a growth of approximately 13%[21] - Inventory levels rose to ¥84,468,113.45, compared to ¥66,765,198.12, indicating a growth of about 26%[21] Future Plans - The company has plans for market expansion and new product development, although specific details were not disclosed in the earnings call[28]